S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$64.55
+0.2%
$40.09
$6.71
$64.57
$4.22B1.143.88 million shs3.98 million shs
Chiasma, Inc. stock logo
CHMA
Chiasma
$3.76
$4.01
$2.77
$5.74
$217.68M1.282.12 million shs147 shs
Chimerix, Inc. stock logo
CMRX
Chimerix
$0.88
-5.4%
$1.08
$0.88
$1.57
$83.17M1.15300,912 shs426,873 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.18
$0.20
$0.09
$3.59
$10.12M2.173.34 million shs801,588 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.29
+3.2%
$18.88
$10.06
$21.72
$351.92M0.8251,149 shs47,212 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
+0.19%+0.28%+60.45%+225.35%+765.28%
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00%0.00%0.00%0.00%0.00%
Chimerix, Inc. stock logo
CMRX
Chimerix
-5.14%-7.94%-10.67%-4.34%-27.51%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-1.08%+15.80%-24.12%+5.14%-93.28%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
+3.16%+1.42%-1.58%+12.41%+81.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
1.5429 of 5 stars
2.13.00.00.03.24.20.0
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
4.2154 of 5 stars
3.54.00.04.12.51.70.6
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.7863 of 5 stars
2.55.00.80.00.01.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
2.27
Hold$50.33-22.02% Downside
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
3.00
Buy$8.00804.57% Upside
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
1.75
ReduceN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0024.42% Upside

Current Analyst Ratings

Latest CHMA, CMRX, ALPN, NATR, and GRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/12/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Peer Perform
4/9/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
3/19/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $47.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$58.88M71.86N/AN/A$5.64 per share11.45
Chiasma, Inc. stock logo
CHMA
Chiasma
$1.11M196.11N/AN/A$1.59 per share2.36
Chimerix, Inc. stock logo
CMRX
Chimerix
$320K246.55N/AN/A$2.17 per share0.41
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.82$1.64 per share11.79$8.36 per share2.31

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)
Chiasma, Inc. stock logo
CHMA
Chiasma
-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/A
Chimerix, Inc. stock logo
CMRX
Chimerix
-$82.10M-$0.92N/AN/AN/A-25,337.96%-37.93%-35.02%5/2/2024 (Estimated)
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$1.41N/AN/AN/AN/A-137.47%5/9/2024 (Estimated)
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.05N/A3.39%12.25%7.75%5/14/2024 (Estimated)

Latest CHMA, CMRX, ALPN, NATR, and GRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A-$0.10-$0.10-$0.10N/AN/A
3/18/2024Q4 2023
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$0.32$0.15+$0.47$0.15$6.90 million$30.85 million
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
2/29/2024Q4 2023
Chimerix, Inc. stock logo
CMRX
Chimerix
-$0.23-$0.20+$0.03-$0.20N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$0.402.07%N/A51.95%N/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/A
7.86
7.86
Chiasma, Inc. stock logo
CHMA
Chiasma
N/A
7.91
7.08
Chimerix, Inc. stock logo
CMRX
Chimerix
N/A
10.25
10.25
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
4.36
4.36
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
75.17%
Chiasma, Inc. stock logo
CHMA
Chiasma
61.68%
Chimerix, Inc. stock logo
CMRX
Chimerix
45.42%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%

Insider Ownership

CompanyInsider Ownership
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
42.30%
Chiasma, Inc. stock logo
CHMA
Chiasma
8.30%
Chimerix, Inc. stock logo
CMRX
Chimerix
10.00%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
6.90%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
4.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
14265.55 million37.82 millionOptionable
Chiasma, Inc. stock logo
CHMA
Chiasma
8557.89 millionN/ANot Optionable
Chimerix, Inc. stock logo
CMRX
Chimerix
7289.21 million80.29 millionOptionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
3154.39 million50.64 millionOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.94 millionOptionable

CHMA, CMRX, ALPN, NATR, and GRTX Headlines

SourceHeadline
Natures Sunshine Products, Inc.s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
finance.yahoo.com - April 4 at 2:56 PM
Natures Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsNature's Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
finance.yahoo.com - March 15 at 7:55 AM
Natures Sunshine Shares Touch 52-Week High After 4Q UpdateNature's Sunshine Shares Touch 52-Week High After 4Q Update
marketwatch.com - March 14 at 8:49 AM
Why Natures Sunshine (NATR) Stock Is Up TodayWhy Nature's Sunshine (NATR) Stock Is Up Today
finance.yahoo.com - March 13 at 1:46 PM
Natures Sunshine Products, Inc.: Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Products, Inc.: Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 13 at 7:45 AM
Natures Sunshine: Q4 Earnings SnapshotNature's Sunshine: Q4 Earnings Snapshot
timesunion.com - March 12 at 8:59 PM
Natures Sunshine (NASDAQ:NATR) Misses Q4 Sales TargetsNature's Sunshine (NASDAQ:NATR) Misses Q4 Sales Targets
finance.yahoo.com - March 12 at 8:59 PM
Natures Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 EarningsNature's Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 Earnings
gurufocus.com - March 12 at 6:04 PM
Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - March 12 at 4:05 PM
Preview: Natures Sunshine Productss EarningsPreview: Natures Sunshine Products's Earnings
benzinga.com - March 11 at 3:30 PM
Natures Sunshine (NATR) Q4 Earnings: What To ExpectNature's Sunshine (NATR) Q4 Earnings: What To Expect
finance.yahoo.com - March 11 at 10:30 AM
Nature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
finance.yahoo.com - February 20 at 7:35 PM
Natures Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature's Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
globenewswire.com - February 20 at 4:05 PM
Is There Now An Opportunity In Natures Sunshine Products, Inc. (NASDAQ:NATR)?Is There Now An Opportunity In Nature's Sunshine Products, Inc. (NASDAQ:NATR)?
finance.yahoo.com - February 6 at 10:21 AM
Natures Sunshine Products: Unconvincing Trajectory Despite ImprovementsNature's Sunshine Products: Unconvincing Trajectory Despite Improvements
seekingalpha.com - January 31 at 4:43 AM
Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024
finance.yahoo.com - January 2 at 8:03 PM
Natures Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the companyNature's Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the company
finance.yahoo.com - December 21 at 3:09 PM
Nature’s Sunshine Recognized with Best Company Culture AwardNature’s Sunshine Recognized with Best Company Culture Award
finance.yahoo.com - December 19 at 10:07 AM
Natures Sunshine Products Stock (NASDAQ:NATR), Quotes and News SummaryNatures Sunshine Products Stock (NASDAQ:NATR), Quotes and News Summary
benzinga.com - December 12 at 11:35 PM
Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93
msn.com - November 27 at 7:16 PM
The Return Trends At Natures Sunshine Products (NASDAQ:NATR) Look PromisingThe Return Trends At Nature's Sunshine Products (NASDAQ:NATR) Look Promising
finance.yahoo.com - November 23 at 6:51 PM
Investing in Natures Sunshine Products (NASDAQ:NATR) a year ago would have delivered you a 108% gainInvesting in Nature's Sunshine Products (NASDAQ:NATR) a year ago would have delivered you a 108% gain
finance.yahoo.com - November 9 at 3:15 PM
Natures Sunshine Products Inc NATRNatures Sunshine Products Inc NATR
morningstar.com - November 8 at 6:51 PM
Nature’s Sunshine Products, Inc. (NASDAQ:NATR) Q3 2023 Earnings Call TranscriptNature’s Sunshine Products, Inc. (NASDAQ:NATR) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 8 at 1:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alpine Immune Sciences logo

Alpine Immune Sciences

NASDAQ:ALPN
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Chiasma logo

Chiasma

NASDAQ:CHMA
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Chimerix logo

Chimerix

NASDAQ:CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Galera Therapeutics logo

Galera Therapeutics

NASDAQ:GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.